CASE REPORT {#s1}
===========

A 27-year-old female with multiple sclerosis on rituximab with neurogenic bladder and frequent urinary tract infections (UTIs) presented to a community hospital with fevers, chills, and vomiting and a positive urinalysis. Despite empiric treatment with vancomycin and piperacillin-tazobactam, her fevers persisted. A computed tomography (CT) scan of the abdomen and pelvis revealed bilateral, small renal abscesses that were up to 2.1 cm in dimension.

Her therapy was broadened to vancomycin and meropenem, but a repeat CT scan 5 days after admission revealed enlarging abscesses. The bilateral collections were aspirated 7 days after admission, but all cultures including aerobic, anaerobic, fungal, and acid-fast cultures failed to isolate a pathogen. She had persistent intermittent fevers above 102°F, but remaining vital signs were stable.

She was transferred to our facility 8 days after admission. Vancomycin was transitioned to linezolid and levofloxacin was added, but her fevers persisted. She had repeat aspiration of the left renal abscess; however, no pathogen was isolated.

From a catheterized specimen, specialized urine culture techniques isolated *Ureaplasma* spp. (*Ureaplasma* culture, Quest Diagnostics, no further speciation). There was insufficient abscess aspirate remaining to be tested for the presence of *Ureaplasma* spp. Doxycycline was orally administered, and all fevers abated within 24 hours. She remained normothermic as the remainder of antibiotics were discontinued.

She was treated with doxycycline for 6 weeks total, as serial CT scans showed slow resolution of her abscesses. Her urinary symptoms improved quickly after initiation of doxycycline, and she remained asymptomatic at follow-up in clinic.

LITERATURE REVIEW {#s2}
=================

We searched PubMed and Embase for the last 30 years for patients with *Ureaplasma* infections outside of urethritis, neonatal, and pregnancy (Appendix). From this search, we excluded patients with transplant (solid organ or bone marrow), surgical site infection, peritoneal dialysis catheters, and children (\<18 years old). We subsequently excluded 1 patient ultimately diagnosed with reactive arthritis that improved on immunosuppression \[[@CIT0001]\]. [Table 1](#T1){ref-type="table"} summarizes the remaining 24 cases.

###### 

Reported Cases of Invasive *Ureaplasma* spp. Infection, Outside of Chorioamnionitis, Urethritis, Surgical Site Infections, and Transplant Recipients, 1989--2019

       Author (Year)                         Case Presentation                                              Microorganism/Method of Diagnosis                                    Antimicrobial Treatment                                           Outcome                                                     Risk Factors
  ---- ------------------------------------- -------------------------------------------------------------- -------------------------------------------------------------------- ----------------------------------------------------------------- ----------------------------------------------------------- --------------------------------------------------------------------------------
  1    Rouard (2019) \[[@CIT0002]\]          88M prosthetic hip infection                                   *U. urealyticum/*16S rRNA PCR and culture                            None                                                              Died of multiple comorbidities                              No known immunocompromising conditions
  2    Gassiep (2017) \[[@CIT0003]\]         51F hip septic arthritis, necrotizing soft tissue infection    *U. urealyticum*/16S rRNA PCR                                        Moxifloxacin                                                      Improved                                                    Mantle cell lymphoma; rituximab + hyper-CVAD, hypogammaglobulinemia
  3    Korytny (2017) \[[@CIT0004]\]         56M shoulder septic arthritis, orchitis, endocarditis          *U. parvum*/16S rRNA PCR (on joint fluid and on aortic valve)        Doxycycline                                                       Improved                                                    CNS lymphoma with chemotherapy (regimen not reported)
  4    Roerdink (2016) \[[@CIT0005]\]        69F bilateral prosthetic knee infection                        *U. urealyticum*/16S rRNA PCR                                        Moxifloxacin + doxycycline                                        Improved                                                    Hodgkin\'s lymphoma/R-CHOP
  5    George (2015) \[[@CIT0006]\]          21F native knee and prosthetic hip infection                   *Ureaplasma* spp./16S rRNA PCR                                       Azithromycin                                                      Improved                                                    JIA on rituximab
  6    Balsat (2014) \[[@CIT0007]\]          18F polyarthritis                                              *U. urealyticum*/ PCR/ESI-MS                                         Levofloxacin + doxycycline                                        Improved                                                    ALL on vincristine, steroids, daunorubicin, L-asparaginase, 1 dose tocilizumab
  7    Farrell (2014) \[[@CIT0008]\]         75M prosthetic knee infection                                  *U. parvum*/PCR/ESI-MS                                               Doxycycline                                                       Improved                                                    No known immunocompromising conditions, colon adenocarcinoma, nephrolithiasis
  8    Deetjen (2014) \[[@CIT0009]\]         20 (gender not specified) brain abscess                        *U. urealyticum*/16S rRNA PCR                                        Doxycycline + clarithromycin                                      Improved                                                    Burkitt\'s lymphoma, rituximab
  9    Yazdani (2012) \[[@CIT0010]\]         68F pyelonephritis, perinephric abscess, psoas abscess         *U. urealyticum*/PCR (further tests not specified)                   Vancomycin + levofloxacin                                         Improved                                                    Mantle cell lymphoma, rituximab
  10   Goulenok (2011) \[[@CIT0011]\]        24M shoulder septic arthritis                                  *U. urealyticum/*culture                                             Doxycycline                                                       Improved                                                    SLE, rituximab
  11   Sköldenberg (2010) \[[@CIT0012]\]     74F prosthetic hip infection                                   *U. urealyticum*/culture                                             Doxycycline                                                       Improved                                                    No known immunocompromising conditions
  12   MacKenzie (2010) \[[@CIT0013]\]       54M polyarthritis, prosthetic hip infection                    *U. parvum* and *Mycoplasma hominis*/16S rRNA                        Moxifloxacin                                                      Died (septic shock; other nosocomial infection suspected)   NHL, rituximab, hypogammaglobulinemia
  13   Tarrant (2009) \[[@CIT0014]\]         100F spontaneous pericarditis, tamponade                       *Ureaplasma* spp./culture                                            Doxycycline                                                       Improved                                                    No known immunocompromising conditions except age
  14   Fenollar (2003) \[[@CIT0015]\]        57F prosthetic valve endocarditis                              *U. parvum*/16S rRNA PCR                                             None                                                              Died (heart failure)                                        No known immunocompromising conditions
  15   Heilmann (2001) \[[@CIT0016]\]        25M polyarthritis                                              *U. urealyticum*/culture                                             Doxycycline + ciprofloxacin + valneumulin (not available in US)   Died (pneumonia)                                            CVID, hypogammaglobulinemia
  16   Heilmann (2001) \[[@CIT0016]\]        34F prosthetic knee septic arthritis                           *U. urealyticum*/culture                                             Doxycycline + valneumulin                                         Improved                                                    CVID, hypogammaglobulinemia
  17   Lapusan (2001) \[[@CIT0017]\]         38M septic arthritis, pneumonia, empyema                       *U. urealyticum*/culture                                             Erythromycin → doxycycline                                        Died (disseminated disease)                                 Hypogammaglobulinemia
  18   Frangogiannis (1998) \[[@CIT0018]\]   31M ankle septic arthritis, endocarditis of unknown etiology   *U. urealyticum*/culture                                             Doxycycline and clarithromycin                                    Improved                                                    CVID, hypogammaglobulinemia
  19   Asmar (1998) \[[@CIT0019]\]           18M knee septic arthritis, bacteremia                          *U. urealyticum*/culture                                             Erythromycin, doxycycline, chloramphenicol → ofloxacin            Improved                                                    Agammaglobulinemia
  20   Puéchal (1995) \[[@CIT0020]\]         30F septic polyarthritis                                       *U. urealyticum*/PCR                                                 Doxycycline, IVIG                                                 Improved                                                    CVID
  21   Forgacs (1993) \[[@CIT0021]\]         53M wrist septic arthritis                                     *U. urealyticum, Mycoplasma hominis, Mycoplasma salvarium*/culture   Doxycycline                                                       Improved                                                    CVID
  22   Lee (1992) \[[@CIT0022]\]             27M septic polyarthritis                                       *Ureaplasma* spp./PCR                                                Doxycycline                                                       Improved                                                    Hypogammaglobulinemia
  23   Lehmer (1991) \[[@CIT0023]\]          38M wrist septic arthritis                                     *U. urealyticum* culture                                             Tetracycline, rosaramicin (macrolide)                             Improved                                                    CVID, hypogammaglobulinemia
  24   Mohiuddin (1991) \[[@CIT0024]\]       22M hip septic arthritis                                       *U. urealyticum* culture                                             Tetracycline                                                      Improved                                                    CVID, hypogammaglobulinemia

Abbreviations: ALL, acute lymphoblastic leukemia; CVID, common variable immune deficiency; ESI-MS, electrospray ionization--mass spectrometry; F, female; hyper-CVAD, cyclophosphamide, doxorubicin, vincristine, dexamethasone; JIA, juvenile idiopathic arthritis; M, male; NHL, non-Hodgkin\'s lymphoma; PCR, polymerase chain reaction; R-CHOP, rituximab, cyclophosphamide, doxorubicin, vincristine, prednisone; SLE, systemic lupus erythematosus.

RESULTS {#s3}
=======

Excluding patients with other known risk factors, humoral immunodeficiencies, either hypogammaglobulinemia or receipt of rituximab, are associated with the majority (17/24, 71%) of invasive *Ureaplasma* infections ([Table 1](#T1){ref-type="table"}). The remaining 7 patients (cases 1, 3, 6, 7, 11, 13, 14) were notable for 2 patients with lymphoma on unreported or other chemotherapy (3, 6), 1 centenarian (12), and 4 patients with a prosthetic implant infection: hip (1, 10), knee (6), and heart valve (13). Nineteen of 24 (79%) patients improved with therapy, and only 1 (4%) patient died of disseminated infection. Septic arthritis was the most common manifestation in this group (21/24, 88%).

DISCUSSION {#s4}
==========

*Ureaplasma* was discovered in 1954 and initially called T-mycoplasma, due to its similarities to *Mycoplasma* species, but notable for its small colony sizes ("T" to indicate "tiny") \[[@CIT0025]\]. Although our report depicts the rarity of invasive *Ureaplasma* infection, earlier cases may have been classified as *Mycoplasma* spp. \[[@CIT0026]\], before the separation of these genera in 1974 \[[@CIT0027]\]. *Ureaplasma* spp. are frequent colonizers in asymptomatic patients, but they have been implicated in chorioamnionitis, neonatal infection, urethritis \[[@CIT0028], [@CIT0029]\], surgical site infections \[[@CIT0030]\], and post-transplant severe hyperammonemia \[[@CIT0031], [@CIT0032]\]. This case report and literature review identifies a subset of patients outside of these populations who are at risk for invasive disease:

1.  1\. Humoral immunodeficiency: Rituximab, a monoclonal antibody against CD20 found on B lymphocytes, was approved by the Food and Drug Administration in 1997 \[[@CIT0033]\], and its use has significantly expanded in recent years to treat a variety of autoimmune and malignant processes. Rituximab has been associated with serious infections as a result of a variety of mechanisms including prolonged B-cell depletion and hypogammaglobulinemia \[[@CIT0034]\]. Interestingly, most reported cases of invasive *Ureaplasma* disease since 2010 have been observed in patients receiving this therapy. Prior studies have shown that patients with hypogammaglobulinemia are more likely to be colonized with *Ureaplasma* and *Mycoplasma* \[[@CIT0035]\]. Furthermore, although neutrophils can phagocytose *Ureaplasma* and *Mycoplasma,* the bacteria remain viable in the absence of antibody. It has been postulated that neutrophils with viable bacteria may facilitate dissemination, tracking to areas of inflammation; however, further studies are needed \[[@CIT0036]\].

2.  2\. Prosthetic implant: We found 4 cases of prosthetic implant infection, 3 joints and 1 heart valve, in patients without known immunodeficiencies. Although rare, *Ureaplasma* may be considered in culture-negative implant infections failing standard therapy.

*Ureaplasma* does not grow on routine media or appear on gram stain; therefore, a specialized culture or 16S rRNA polymerase chain reaction (PCR) assay must be employed. Empiric therapy may be indicated in settings of severe infection, owing to these tests\' long turnaround times. Tetracyclines, macrolides, and quinolones all have activity against *Ureaplasma* spp. Although susceptibility testing is not widely available, there has been concern for increasing resistance globally \[[@CIT0037]\]. Consequently, despite treatment with levofloxacin, our patient only improved when doxycycline was administered. In patients with severe illness due to suspected or confirmed *Ureaplasma* spp. infection, agents from 2 different classes can be used to increase the likelihood of therapeutic success \[[@CIT0038]\].

CONCLUSIONS {#s5}
===========

This case review should alert providers to consider *Ureaplasma* spp. in infected patients with negative standard cultures, who have humoral immunodeficiency, whether it be congenital (eg, hypogammaglobulinemia) or iatrogenic (eg, anti-CD20 therapy). Specialized culture or PCR is necessary for confirmation of diagnosis. Therapy involves selection of an agent from the tetracycline, macrolide, and/or quinolone classes.
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